Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...

The company will use the proceeds to test its gene therapy XC001 in two Phase II studies involving patients with cardiovascular disease.

The firm has discussed positive Phase I results on BCB-276 with the FDA and plans to move it directly to a registrational trial by year-end.

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

Chinese regulators approved the drug for the same subset of advanced, previously treated EGFR-mutated NSCLC patients in 2023.

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

The gene therapy for an undisclosed central nervous system disease is based on JCR's delivery technology and Modalis' epigenome editing platform.

The grants, awarded in partnership with the Authority of Social Contribution-Ma'an, will fund 11 research projects across multiple disease areas.

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.